<?xml version='1.0' encoding='utf-8'?>

<rss version="2.0">
  <channel>
    <title>The Federal Register</title>
    <link>http://thefederalregister.com/b.p/agency/Food_and_Drug_Administration/2007-11-26/</link>
    <description>Daily Publications of Meetings and Rules Changes for the Federal Government</description>
    <pubDate>Sat, Nov 22 2008 11:00:00 GMT</pubDate>
    <lastBuildDate>Sat, Nov 22 2008 11:00:00 GMT</lastBuildDate>
    <webMaster>info@thefederalregister.com</webMaster>
    <item>
  <title><![CDATA[  New Animal Drugs For Use in Animal Feeds; Florfenicol ]]></title>
  <link>http://thefederalregister.com/d.p/2007-11-26-E7-22942</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect the approval of a supplemental new animal 
drug application (NADA) filed by ScheringPlough Animal Health Corp. 
The supplemental NADA provides for the use of florfenicol by veterinary 
feed directive (VFD) for the control of mortality in freshwaterreared 
salmonids due to furunculosis associated with Aeromonas salmonicida.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2007-11-26-E7-22942</guid>
  <pubDate>Mon, Nov 26 2007 11:00:00 GMT</pubDate>
</item>
<item>
  <title><![CDATA[  Determination That ELOXATIN (Oxaliplatin for Injection), 50 and  100 Milligrams Per Vial, Sterile Lyophilized Powder]]></title>
  <link>http://thefederalregister.com/d.p/2007-11-26-E7-22973</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) has determined that 
ELOXATIN (oxaliplatin for injection), 50 and 100 milligrams (mg) per 
vial, sterile lyophilized powder for injection, was not withdrawn from 
sale for reasons of safety or effectiveness. This determination will 
allow FDA to approve abbreviated new drug applications (ANDAs) for 
oxaliplatin sterile lyophilized powder for injection, 50 and 100 mg/
vial.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2007-11-26-E7-22973</guid>
  <pubDate>Mon, Nov 26 2007 11:00:00 GMT</pubDate>
</item>
</channel>
</rss>

